OpCT 001
Alternative Names: OpCT-001Latest Information Update: 25 Jan 2024
At a glance
- Originator BlueRock Therapeutics; Fujifilm Cellular Dynamics; Opsis Therapeutics
- Class Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Retinal disorders
Most Recent Events
- 23 Jan 2024 BlueRock Therapeutics exercises exclusive option to license OpCT 001 from FUJIFILM Cellular Dynamics and Opsis Therapeutics
- 23 Jan 2024 BlueRock Therapeutics plans to files an IND application for Retinal disorders in 2024
- 23 Jan 2024 BlueRock Therapeutics plans a clinical trial in Retinal disorders